These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 27091885)
1. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885 [TBL] [Abstract][Full Text] [Related]
3. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection. Melchore JA; Berdovich D PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593 [TBL] [Abstract][Full Text] [Related]
4. Achieving "Zero" Defects for Visible Particles in Injectables. Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141 [TBL] [Abstract][Full Text] [Related]
5. Container Closure Integrity Testing-Practical Aspects and Approaches in the Pharmaceutical Industry. Brown H; Mahler HC; Mellman J; Nieto A; Wagner D; Schaar M; Mathaes R; Kossinna J; Schmitting F; Dreher S; Roehl H; Hemminger M; Wuchner K PDA J Pharm Sci Technol; 2017; 71(2):147-162. PubMed ID: 27789803 [TBL] [Abstract][Full Text] [Related]
6. Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach. Langille SE PDA J Pharm Sci Technol; 2020; 74(3):359-366. PubMed ID: 31732691 [TBL] [Abstract][Full Text] [Related]
7. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations. Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504 [TBL] [Abstract][Full Text] [Related]
8. Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle Visibility. Mazaheri M; Saggu M; Wuchner K; Koulov AV; Nikels F; Chalus P; Das TK; Cash PW; Finkler C; Levitskaya-Seaman SV; Case J; Parsons J; Gonzalez K J Pharm Sci; 2024 Mar; 113(3):616-624. PubMed ID: 37802369 [TBL] [Abstract][Full Text] [Related]
10. Industry perspective on the medical risk of visible particles in injectable drug products. Bukofzer S; Ayres J; Chavez A; Devera M; Miller J; Ross D; Shabushnig J; Vargo S; Watson H; Watson R PDA J Pharm Sci Technol; 2015; 69(1):123-39. PubMed ID: 25691720 [No Abstract] [Full Text] [Related]
11. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products. Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951 [TBL] [Abstract][Full Text] [Related]
12. Origin, result and measurement of USP "essentially free" inspection for visible contaminating particles. Knapp JZ PDA J Pharm Sci Technol; 2000; 54(3):218-32. PubMed ID: 10927913 [TBL] [Abstract][Full Text] [Related]
13. A Risk- and Science-Based Approach to the Acceptance Sampling Plan Inspection of Protein Parenteral Products. Spasoff A; Bennis A; Atkinson S; Elliott C; Freund E; Narhi L J Pharm Sci; 2018 Sep; 107(9):2306-2309. PubMed ID: 29859961 [TBL] [Abstract][Full Text] [Related]